GVK Biosciences has entered into a 50:50 joint venture (JV) with INC Research (INC) to form INC GVK Bio Pvt Ltd.
The JV will establish a dedicated resource capability to offer phase I-IV clinical development programs in India for INC's global clients.
The joint venture will enable INC Research to conduct its global clinical trials in the areas of oncology, CNS, infectious diseases and Paediatrics involving phase I-IV studies. GVK Bio currently, provides contract research services to a rapidly growing base of global pharmaceutical and biotechnology companies.
Commenting on the new initiative, G V Sanjay Reddy, CEO, GVK Bio said, "The joint venture provides an opportunity for GVK Bio to gain access to INC Research's global reach while leveraging on its India-based clinical research capabilities".
Kelvin Logan, president of INC Research Europe stated, "Our international base of operations has expanded strategically this last year, with the addition of several new offices in Europe and now India. This joint venture will allow INC Research to further solidify and expand its presence within the world CRO market".
GVK Bio is one of India's premier CROs, providing an integrated platform of research services across the pharma R&D value chain to a growing number of global pharma and biotech companies. The company combines science, innovation and resources to help clients address their drug discovery and development challenges. Currently, the company has more than 1,200 employees spread across facilities in Hyderabad, Chennai and Gurgaon.